Myriad Genetics (MYGN) commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network, NCCN, as the guidelines underscore the critical role of the company’s portfolio of offerings across the patient’s prostate cancer journey. These guidelines further validate Myriad’s ability to streamline the diagnostic process and enhance personalized treatment options.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics initiated with a Neutral at UBS
- Myriad announces its Prolaris test is still classified as ‘Advanced Tool’
- Leerink downgrades Myriad Genetics on reimbursement, competitive headwinds
- Myriad Genetics downgraded to Market Perform from Outperform at Leerink
- Myriad Genetics Settles Shareholder Lawsuits with Reforms